|
1
|
Zhang Y, Shi J, Huang H, Ren J, Li N and
Dai M: Burden of colorectal cancer in China. Zhonghua Liu Xing Bing
Xue Za Zhi. 36:709–714. 2015.(In Chinese). PubMed/NCBI
|
|
2
|
Kanwar SS1, Poolla A and Majumdar AP:
Regulation of colon cancer recurrence and development of
therapeutic strategies. World J Gastrointest Pathophysiol. 3:1–9.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lu H, Ouyang W and Huang C: Inflammation,
a key event in cancer development. Mol Cancer Res. 4:221–233. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang S, Chen F and Tang L: IL-32 promotes
breast cancer cell growth and invasiveness. Oncol Lett. 9:305–307.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yousif NG, Al-Amran FG, Hadi N, Lee J and
Adrienne J: Expression of IL-32 modulates NF-κB and p38 MAP kinase
pathways in human esophageal cancer. Cytokine. 61:223–227. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ishigami S, Arigami T, Uchikado Y,
Setoyama T, Kita Y, Sasaki K, Okumura H, Kurahara H, Kijima Y,
Harada A, et al: IL-32 expression is an independent prognostic
marker for gastric cancer. Med Oncol. 30:4722013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zeng Q, Li S, Zhou Y, Ou W, Cai X, Zhang
L, Huang W, Huang L and Wang Q: Interleukin-32 contributes to
invasion and metastasis of primary lung adenocarcinoma via
NF-kappaB induced matrix metalloproteinases 2 and 9 expression.
Cytokine. 65:24–32. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nishida A, Andoh A, Inatomi O and Fujiyama
Y: Interleukin-32 expression in the pancreas. J Biol Chem.
284:17868–17876. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Heinhuis B, Plantinga TS, Semango G,
Küsters B, Netea MG, Dinarello CA, Smit JWA, Netea-Maier RT and
Joosten LAB: Alternatively spliced isoforms of IL-32 differentially
influence cell death pathways in cancer cell lines. Carcinogenesis.
37:197–205. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Goda C, Kanaji T, Kanaji S, Tanaka G,
Arima K, Ohno S and Izuhara K: Involvement of IL-32 in
activation-induced cell death in T cells. Int Immunol. 18:233–240.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Oh JH, Cho MC, Kim JH, Lee SY, Kim HJ,
Park ES, Ban JO, Kang JW, Lee DH, Shim JH, et al: IL-32γ inhibits
cancer cell growth through inactivation of NF-κB and STAT3 signals.
Oncogene. 30:3345–3359. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fukushima Y, Iinuma H, Tsukamoto M,
Matsuda K and Hashiguchi Y: Clinical significance of microRNA-21 as
a biomarker in each Dukes' stage of colorectal cancer. Oncol Rep.
33:573–582. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Itzkowitz SH and Yio X: Inflammation and
cancer IV. Colorectal cancer in inflammatory bowel disease: The
role of inflammation. Am J Physiol Gastrointest Liver Physiol.
287:G7–G17. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Coussens LM and Werb Z: Inflammation and
cancer. Nature. 420:860–867. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Semango G, Heinhuis B, Plantinga TS, Blokx
WAM, Kibiki G, Sonda T, Mavura D, Masenga EJ, Nyindo M, van der Ven
AJAM and Joosten LAB: Exploring the role of IL-32 in HIV-related
Kaposi sarcoma. Am J Pathol. 188:196–203. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang Y, Yang Y, Zhu Y, Li L, Chen F and
Zhang L: Polymorphisms and expression of IL-32: Impact on genetic
susceptibility and clinical outcome of lung cancer. Biomarkers.
22:165–170. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Park JS, Choi SY, Lee JH, Lee M, Nam ES,
Jeong AL, Lee S, Han S, Lee MS, Lim JS, et al: Interleukin-32β
stimulates migration of MDA-MB-231 and MCF-7 cells via the
VEGF-STAT3 signaling pathway. Cell Oncol (Dordr). 36:493–503. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Suga H, Sugaya M, Miyagaki T, Kawaguchi M,
Fujita H, Asano Y, Tada Y, Kadono T and Sato S: The role of IL-32
in cutaneous T-cell lymphoma. J Invest Dermatol. 134:1428–1435.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Seo EH, Kang J, Kim KH, Cho MC, Lee S, Kim
HJ, Kim JH, Kim EJ, Park DK, Kim SH, et al: Detection of expressed
IL-32 in human stomach cancer using ELISA and immunostaining. J
Microbiol Biotechnol. 18:1606–1612. 2008.PubMed/NCBI
|
|
21
|
Nicholl MB, Chen X, Qin C, Bai Q, Zhu Z,
Davis MR and Fang Y: IL-32α has differential effects on
proliferation and apoptosis of human melanoma cell lines. J Surg
Oncol. 113:364–369. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Park ES, Yoo JM, Yoo HS, Yoon DY, Yun YP
and Hong J: IL-32γ enhances TNF-α-induced cell death in colon
cancer. Mol Carcinog. 53 Suppl 1:E23–E35. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tsai CY, Wang CS, Tsai MM, Chi HC, Cheng
WL, Tseng YH, Chen CY, Lin CD, Wu JI, Wang LH and Lin KH:
Interleukin-32 increases human gastric cancer cell invasion
associated with tumor progression and metastasis. Clin Cancer Res.
20:2276–2288. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sorrentino C and Di Carlo E: Expression of
IL-32 in human lung cancer is related to the histotype and
metastatic phenotype. Am J Respir Crit Care Med. 180:769–779. 2009.
View Article : Google Scholar : PubMed/NCBI
|
